Rhythm Pharmaceuticals, Inc.
RYTMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The $6.12B market capitalization puts RYTM squarely in mid-cap range for its industry. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Market Cap
$6.12B
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
-141.98
EPS (TTM)
$-3.12
EPS (Fwd)
$-0.63
ROE
-117.1%
ROA
-31.0%
Cash
$330.9M
Total Debt
$109.8M
Free CF
-$130.6M
52W Change
-20.0%
Annual Financials
Cash vs Debt
Where RYTM stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RYTM finished 11.03% below its 150-day moving average ($96.85) and 11.86% below its 200-day moving average ($97.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RYTM overbought or oversold?
At the October 19, 2026 close, RYTM's RSI(14) was 18.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $330.9M in cash comfortably exceeding the $109.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$130.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -117.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $23.6M (2022) to $189.8M (2025), reflecting a 703% increase over the period.
With a beta above 1.5, RYTM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Rhythm Pharmaceuticals, Inc.'s trajectory.